AD has to be understood to bring sustainable improvements to patients. I'm convinced that by expanding our knowledge about neurodegenerative diseases, we are able to limit and counteract harmful disease progression. Therefore, I studied Biotechnology to understand how biological systems work and how we can control them for our benefit. I graduated in 2017 from ETH Zurich (M.Sc. ETH), where I was taught scientific work on basic research. After graduation, I joined the University Hospital of Basel for my PhD studies to work in translational research on neuromodulation of glial cells. Bottneuro allows us to bring translation from research to clinical application a step further and bring direct benefits to patients.